Novartis Pharmaceuticals (Pvt) Ltd.
Pharmaceutical company · 140 brands · 173 molecules
Ranked #7 of 44 companies in Antineoplastics
Company overview
Novartis Pharmaceuticals (Pvt) Ltd. is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 140 product registrations across 173 distinct molecules. It is the 115th largest registrant in Pakistan by product count, and ranks 7th of 44 in Antineoplastics. Its portfolio is concentrated in Antineoplastics and Neuro. DRAP has issued 5 alerts involving its products.
Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.
Products by Novartis
155 products matched in our catalogue · showing 80 — each with its observed price and DRAP approved ceiling.
Price ceiling age
DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.
Top molecules by brand count
Therapeutic classes
Conditions treated
Price band (DRAP official ceilings)
Regulatory record
5 alerts in the DRAP feed we track.
Competitive set
Companies whose registered portfolio overlaps most with this one.
Portfolio whitespace
Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.
Get the full profile for Novartis
This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.
Request this brief See what’s included